生物活性

• 描述BMS-582949 is a potent and selective p38 mitogen-activated protein kinase (p38 MAPK) inhibitor with IC50 of 13 nM,inhibiting both p38 kinase activity and activation of p38.
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT00570752	Vascular Diseases	Phase 2	Completed	-	United States, Florida ... more >> Southeast Clinical Research, Llc Chiefland, Florida, United States, 32626 Jacksonville Center For Clinical Research - Univ Campus Jacksonville, Florida, United States, 32216 Florida Cardiovascular Institute Tampa, Florida, United States, 33609 United States, Indiana Phillip D. Toth, Md Indianapolis, Indiana, United States, 46260 United States, Kentucky L-Marc Research Center Louisville, Kentucky, United States, 40213 Commonwealth Biomedical Research, Llc Madisonville, Kentucky, United States, 42431 United States, Massachusetts Mgh Cardiac Mr Pet Ct Program Boston, Massachusetts, United States, 02114 United States, Michigan Troy Internal Medince Pc/Research Troy, Michigan, United States, 48098 United States, Minnesota Radiant Research, Inc. Edina, Minnesota, United States, 55435 United States, New York Mount Sinai School Of Medicine Imaging Science Laboratories New York, New York, United States, 10029 United States, North Carolina The Lipid Center Statesville, North Carolina, United States, 28677 United States, Ohio Metabolic And Atherosclerosis Research Center Cincinnati, Ohio, United States, 45212 Sterling Research Group Cincinnati, Ohio, United States, 45219 United States, Pennsylvania Hospital Of The University Of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 United States, Texas Radiant Research, Inc. Dallas, Texas, United States, 75231 Baylor College Of Medicine Houston, Texas, United States, 77030 Mcallen Heart Clinic Mc Allen, Texas, United States, 78503 Collapse <<
  NCT00605735	Rheumatoid Arthritis, NOS	Phase 2	Completed	-	-
  NCT00162292	Rheumatoid Arthritis	Phase 1	Completed	-	United States, California ... more >> Desert Medical Advances Palm Desert, California, United States, 92260 Boling Clinical Trials Upland, California, United States, 91786 United States, Florida Delray Research Associates Delray Beach, Florida, United States, 33484 Ocala Rheumatology Research Center Ocala, Florida, United States, 34474 United States, Massachusetts Phase Iii Clinical Research Fall River, Massachusetts, United States, 02720 United States, Texas Covance Clinical Research Unit Inc. Dallas, Texas, United States, 75247 Radiant Research San Antonio Northeast San Antonio, Texas, United States, 78217 Healthcare Discoveries, Inc San Antonio, Texas, United States, 78229 Mexico Local Institution Metepec, Estado De Mexico, Mexico, 52140 Local Institution Leon, Guanajuato, Mexico, 37520 Collapse <<

• 更多
• 参考文献

• [1] Emami H, Vucic E, et al. The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial. Atherosclerosis. 2015 Jun;240(2):490-6.

  [2] Liu C, Lin J, et al. Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f] [1,2,4] triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases. J Med Chem. 2010 Sep 23;53(18):6629-39.